Neuronal Nicotinic Receptors - July 2008
Neuronal nicotinic receptor ligands are fast proceeding through clinical development as exciting candidates for multiple CNS disorders including Alzheimer's disease; Schizophrenia; ADHD; Depression; Pain and Adiction.
Are you involved in these areas; are you developing nicotinic receptor ligands? If so UpdatesPlus is for you. This service, brought to you from the pharmaceutical analysts, LeadDiscovery, not only delivers all key breaking research, drug development news and clinical trials in this area, it also analyzes it.
Published monthly along with a fully up to date pipeline of nicotinic receptor therapeutics, UpdatesPlus offers a key insight into the strategy and development within the nicotinics arena. Offering an ideal intelligence tool for everyone from brand managers to medical directors and preclinical managers, UpdatesPlus is a must for all involved in this exciting new field of medicine
See December 2007 edition now (free sample copy)
Table of Contents
What's in the July 2008 edition of UpdatesPlus-Nicotinic Receptors?
- Sanofi-Aventis suspend phase 2 SSR180711 study in Alzheimer’s disease patients: LeadDiscovery speculates on the reason for the recent suspension of this study including an analysis of data published by NeuroSearch suggesting that amyloid may reduce the efficacy of α7 agonists
- Information on new patents including: Pfizer’s α7 modulators; Memory Pharmaceuticals’ α7 partial agonists; Abbott’s combinatorial α4β2 ligand/positive modulator approach to pain. LeadDiscovery speculate that Abbott may be planning to develop its α4β2 agonist, ABT-894 in combination with an α4β2 modulator once ABT-894 has been approved
- Pfizer report dramatic drop in Chantix/Champix sales: While international revenues on Chantix/Champix sales grew to $98 million, an increase of 197%, reflecting launches in new regions, Pfizer have reported that in the US Chantix revenues have declined by as much as 35% compared with peak quarter sales. LeadDiscovery reports of some of the strategies that Pfizr may be adopting to slow this fall
- AstraZeneca/Targacept continue a series of studies evaluating interaction of AZD3480 with CYP2D6 substrates: AstraZeneca announces a study evaluating the interaction of AZD3480 with Aricept
- NeuroSearch announces ABT-894 efficacy in phase 2 ADHD study: NeuroSearch and Abbott are co-developing ABT-894 for the treatment of ADHD (as well as pain). LeadDiscovery evaluates the implication of new phase 2 ADHD study announced by NeuroSearch
- Mixed α4β2 and α7 antagonism required for optimal antidepressant activity? NeuroSearch researchers have conducted an in vivo study demonstrating the effect of mecamylamine as well as selective α4β2 and α7 antagonists in mouse models of depression. LeadDiscovery analyzes these data and implications
- Full and up to date pipeline
Pricing & Delivery: UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and also ready for use within a presentation setting
2008 issues:
About UpdatesPlus: Through DailyUpdates, LeadDiscovery has access to one of the most comprehensive sources of information for the drug development sector. UpdatesPlus takes this information and uses our industrial experience to provide a monthly analysis of breaking activity in selected indications and molecular targets. If this is the first time that you have heard of UpdatesPlus please take a moment to have a look at an example. If you would find such a service of use in your area contact us now.
Other users found this report page using the following search terms: euronal Nicotinic Receptors nicotinic receptors cognition cognitive cias alzheimer amyloid depression adhd smoking cessation alpha7 alpha6 alpha4beta2 nicotinic adhd alzheimers nicotine memory nicotinic receptors neuronal adhd receptor abt894 nicotinics 2008 monthly neurosearch
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.